Endometrial cancer, a common gynecological malignancy, leaves considerable unmet needs for patients with advanced or recurrent disease. GSK‘s (NYSE:GSK) Jemperli (dostarlimab), a PD-1 receptor antagonist, brings hope to the numerous women diagnosed with this cancer each year. As the first immunotherapy approved for patients with deficient mismatch repair (dMMR) endometrial cancer, dostarlimab has the potential…

FDA has approved Jemperli from GSK (NYSE:GSK) for adult patients with mismatch repair-deficient or advanced endometrial carcinoma (dMMR). GSK predicts Jemperli will generate peak sales of $1.4 billion to $2.8 million. The drug is indicated for adults with dMMR-related or advanced endometrial carcinoma who have progressed after a previous platinum-containing regimen. This drug is not…

GSK (LSE/NYSE:GSK) has shared positive headline results from a planned interim analysis of Part 1 of a Phase 3 study of adults with primary advanced or recurrent endometrial cancer. In the study, patients in the Jemperli (dostarlimab) arm also received chemotherapy (carboplatin-paclitaxel) followed by Jemperli alone. The study tested the treatment regimen against chemotherapy with…

Cancer treatment has been a critical point for clinical diagnostics. Over the years, various treatment approaches- from naked nucleic acid-based therapy, targeting microRNAs, oncolytic virotherapy, and suicide-gene-based therapy to CRISPR/Cas-9-based therapy. More recently, drug-based therapy has also emerged as a promising area for cancer therapeutics. Regarding drug administration, a major buzz has been created around…